Physician profile
Vicky H Lee
NPI 1740239342
$11,599.44
in general payments reported to CMS, 2019-2025
46 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $3,362 · 2021: $3,968 · 2022: $1,890 · 2024: $139 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.81 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,932.44 | 2019-2025 | Tagrisso, Lynparza |
| Pfizer INC. | $2,402.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,643.85 | 2019-2022 | |
| Incyte Corporation | $1,500.48 | 2019-2025 | Jakafi |
| Beigene, LTD. | $450.00 | 2020 | |
| Janssen Biotech, INC. | $309.18 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $308.35 | 2019-2025 | Fruzaqla |
| Genzyme Corporation | $176.07 | 2019-2021 | |
| Exelixis INC. | $148.18 | 2024-2025 | Cabometyx |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Puma Biotechnology, INC. | $131.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $128.67 | 2019-2025 | Keytruda, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $116.17 | 2019-2021 | |
| Intuitive Surgical, INC. | $102.61 | 2022 | |
| Clovis Oncology, INC. | $100.31 | 2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.